SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Follow-up) — Frederick Cook

PatientFrederick Cook
Date of birth1961-06-10
IdentifiersMRN HR-EX006-SYN; SSN (made up) 000-06-4471
Document date2026-09-29
AuthorHarriet Okafor-Brandt, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twelve-week review of blood pressure and lipids three weeks after a gout flare on hydrochlorothiazide. [S]

History of Present Illness

Mr. Cook returns three weeks after the same-day visit for gout of his right big toe. The pain settled within four days of colchicine, he took the last tablet five days after starting, and he had no diarrhea or muscle aches. He has had no further attacks. He continues hydrochlorothiazide, amlodipine, atorvastatin and aspirin without missed doses. His home readings average 132/80. He has had no stroke symptoms. His Social Security retirement benefits and Medicare have been approved, and he has signed a six-month lease on his room. He is writing most mornings and says he feels steadier. [S]

ElementDetail
GoutSettled within four days on colchicine; no further attacks
Home blood pressureAverage 132/80
Medicine effectsNo diarrhea, muscle aches or bleeding
SocialBenefits and Medicare approved; six-month lease

Review of Systems

SystemResultFinding
MusculoskeletalNegativeRight big toe back to normal; no other joint pain; no muscle aches
CardiovascularNegativeNo chest pain or ankle swelling
NeurologicalNegativeNo weakness, numbness, speech trouble, or loss of vision
PsychiatricNegativeMood steadier; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydrochlorothiazide 25 mg tablet, one tablet by mouth each morningonce daily in the morningOral route2026-07-21 to 2026-09-29completedS
Amlodipine 5 mg tablet, one tablet by mouth dailyonce dailyOral route2026-07-21activeS
Atorvastatin 40 mg tablet, one tablet by mouth dailyonce dailyOral route2026-07-21activeS
Aspirin 81 mg delayed-release tablet, one tablet by mouth dailyonce dailyOral route2026-07-21activeS
Losartan 50 mg tablet, one tablet by mouth dailyonce dailyOral route2026-09-29activeS
Colchicine 0.6 mg tablet: two tablets at once, one more an hour later, then one tablet twice a day until the flare settles, for up to a week1.2 mg, then 0.6 mg an hour later, then 0.6 mg twice daily for up to a weekOral route2026-09-08 to 2026-09-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-29Body height175cmS
2026-09-29Body weight75kgS
2026-09-29Body mass index (BMI) [Ratio]24.5kg/m2S
2026-09-29Systolic blood pressure134mm[Hg]S
2026-09-29Diastolic blood pressure80mm[Hg]S
2026-09-29Heart rate68/minS
2026-09-29Respiratory rate14/minS
2026-09-29Body temperature36.5CelS
2026-09-29Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-29Urate [Mass/volume] in Serum or Plasma8.4mg/dL3.5-7.2 mg/dLHighS
2026-09-29Sodium [Moles/volume] in Serum or Plasma137mmol/L136-145 mmol/LNormalS
2026-09-29Potassium [Moles/volume] in Serum or Plasma3.7mmol/L3.5-5.1 mmol/LNormalS
2026-09-29Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.74-1.35 mg/dLNormalS
2026-09-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M80mL/min/{1.73_m2}60 or moreNormalS
2026-09-29Cholesterol [Mass/volume] in Serum or Plasma142mg/dL<=199 mg/dLNormalS
2026-09-29Cholesterol in HDL [Mass/volume] in Serum or Plasma48mg/dL>=40 mg/dLNormalS
2026-09-29Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation68mg/dLBelow 100NormalS
2026-09-29Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
2026-09-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-52 U/LNormalS

Physical Exam

Vital signs recorded on 2026-09-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 134/80, pulse 68, weight 75.0 kg
Right footFirst metatarsophalangeal joint normal, no swelling or tenderness; no tophi
NeckSoft right carotid bruit, unchanged

Problems

ProblemClinical statusVerificationCodeProvenance
Elevated blood pressure at the first visit, 166/94 mmHg (average of two seated readings), without a previous diagnosis of hypertension; no symptoms; out-of-office confirmation with a week of home readings requestedresolvedconfirmed R03.0S — Synthetic presenting finding at re-entry; superseded by the diagnosis at the second visit.
Essential hypertension, stage 2, confirmed by home readings averaging 154/90 mmHg; no left ventricular hypertrophy on ECG; urine albumin normalactiveconfirmed I10S — Synthetic modern diagnosis made at the second visit.
Right carotid bruit heard at the first visit in a man with no symptoms of stroke or transient ischemic attack; carotid duplex ultrasound and vascular neurology consultation requestedresolvedconfirmed R09.89S — Synthetic examination finding; superseded by the duplex result at the second visit.
Asymptomatic atherosclerotic stenosis of the right internal carotid artery, 50 to 69 percent by duplex ultrasound, with less than 50 percent plaque on the left; no stroke or transient ischemic attack; managed with best medical therapy (blood pressure control, a statin and low-dose aspirin) and yearly duplex surveillanceactiveconfirmed I65.21S — Synthetic modern diagnosis made at the vascular neurology consultation; not a claim about his real arteries.
Recent release from about six years of incarceration: re-entering community life on parole at 65, establishing primary care with no medical records yet received, a rented room, no earned income, and a public reputation he feels as a burdenactiveconfirmed Z65.2S — Synthetic modern social problem anchored to his documented imprisonment and parole.
Acute gout of the right first metatarsophalangeal joint, a first flare seven weeks after starting hydrochlorothiazide, diagnosed clinically (sudden overnight onset, redness, swelling and exquisite tenderness of the big toe, no fever); treated with low-dose colchicine; resolvedresolvedconfirmed M10.271S — Synthetic adverse drug effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure, seated, average of two readingsEvery visitCompleted today134/80 mmHg
Self-managementHome blood pressure monitoringAt diagnosis and after each treatment changeCompleted todayAverage 132/80; repeat after the switch to losartan
LaboratorySodium, potassium, creatinine and eGFRBaseline; early after starting a diuretic or an ARB; then every 6 monthsCompleted todaySodium 137, potassium 3.7 mmol/L, creatinine 1.04 mg/dL, eGFR 80; baseline before losartan; repeat ordered for one to two weeks after starting
LaboratoryLipid panelBaseline; 4 to 12 weeks after starting a statin; then every 3 to 12 monthsCompleted todayTotal cholesterol 142, HDL 48, LDL 68, triglycerides 130 mg/dL, ten weeks after starting atorvastatin; LDL down 54 percent
LaboratoryALT on a statinBaseline, then with the first lipid check or with symptomsCompleted today26 U/L
LaboratorySerum urate after a gout flareTwo to four weeks after the flare settles, and on any change in therapyCompleted today8.4 mg/dL on hydrochlorothiazide
Medication safetyReview of drugs that raise urateAfter a gout flareCompleted todayHydrochlorothiazide stopped; losartan started; low-dose aspirin continued because its benefit outweighs its small effect on urate
Medication safetyUrate-lowering therapyAfter each flareNot indicatedSingle flare; no kidney disease, tophi, stones, or urate above 9 mg/dL
Medication safetyAntiplatelet adherence and bleedingEvery visitCompleted todayNo bleeding
Medication safetyStatin adherence and muscle symptomsEvery visitCompleted todayNo muscle symptoms, including during colchicine
ImagingCarotid duplex ultrasound for known 50 percent or greater stenosis on medical therapyAt diagnosis, then yearlyUp to dateNext duplex due in about ten months
Self-managementStroke warning signs (BE FAST) and calling 911Every visitCompleted todayNo symptoms
SurveyDepression screen (PHQ-9)AnnuallyUp to datePHQ-9 7 at intake; mood steadier by interview; repeat planned at the next visit
Self-managementRe-entry social needs: housing, income, benefits, recordsEvery visit until settledCompleted todaySocial Security and Medicare approved; six-month lease

Goal progress:

Immunizations given today: Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2 [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (Jones DW, et al. Hypertension 2025;82:e212-e316) (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and stroke/TIA monographs (2026); 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association (Bushnell C, et al. Stroke 2024;55:e344-e424) (2024); 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy SM, et al. Circulation 2019;139:e1082-e1143) (2018); 2020 American College of Rheumatology Guideline for the Management of Gout (FitzGerald JD, et al. Arthritis Care Res 2020;72(6):744-760) (2020)

Follow-up: Potassium and creatinine in one to two weeks. Review in four weeks. Next scheduled visit 2026-10-27: sixteen-week review: blood pressure, potassium and kidney function on losartan, mood, social needs and stroke prevention. [S]